LANCY(002612) 国元证券·2025-04-08 04:43Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [4]. Core Insights - The company reported a stable growth in net profit excluding non-recurring items, with a 1.38% year-on-year increase in adjusted net profit to CNY 2.57 billion and an 11.3% increase in net profit excluding non-recurring items to CNY 2.18 billion for 2024 [1][2]. - The revenue for 2024 was CNY 56.91 billion, showing a slight year-on-year decline, while the gross margin improved to 58.85%, up 1.41 percentage points [1]. - The company is actively expanding its medical beauty segment, with a 3.47% year-on-year revenue growth in this area, contributing CNY 27.84 billion in revenue [2]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of CNY 56.91 billion, with a net profit of CNY 2.57 billion, and a net profit margin of 5.19%, reflecting a 0.29 percentage point increase year-on-year [1]. - The medical beauty segment generated CNY 27.84 billion in revenue, with a gross margin of 54.42% [2]. - The women's clothing segment saw a revenue decline of 2.97% to CNY 19.25 billion, while the infant and toddler segment decreased by 5.53% to CNY 9.21 billion [2]. Strategic Developments - The company has been actively pursuing external growth through acquisitions, with a total investment of CNY 9.5 billion planned for its medical management subsidiary [3]. - By the end of 2024, the company had established seven medical beauty acquisition funds with a total scale of CNY 28.37 billion, aiming to enhance its medical beauty business [3]. Earnings Forecast - The company projects earnings per share (EPS) of CNY 0.62, CNY 0.66, and CNY 0.69 for the years 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios (P/E) of 26, 24, and 23 [4].